Evidence map›Paper›PMID 40661594›Full record

ArticlebioRxiv : the preprint server for biology2025

Structural Identification of Major Molecular Determinants for Phosphotyrosine Recognition in Tyrosine Kinases Reveals Tumour Promoting and Suppressive Functions.

Nuo Cheng, Luis R Millán-Barea, Marc Creixell, Alexis R Barr, Yi Wen Kong, Brian A Joughin, Cécile K Lopez, Jette Lengefeld, James Clarke, Chuan Liu and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nuo ChengCancer Research UK Cambridge Institute, University of Cambridge, UK.ORCID 0000-0002-2614-8682
Luis R Millán-BareaCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Marc CreixellCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Alexis R BarrMRC Laboratory of Medical Sciences, London, UK.
Yi Wen KongCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Brian A JoughinCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Cécile K LopezDepartment of Haematology, University of Cambridge, Cambridge, UK.
Jette LengefeldCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
James ClarkeCancer Research UK Cambridge Institute, University of Cambridge, UK.
Chuan LiuDepartment of Biomedical Engineering, Pennsylvania State University, University Park, State College, PA, 16802, USA.
Ganapathy SriramCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Tania J González-RoblesCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Bert van de KooijCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Simonas SavickasDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads B221, Kgs. Lyngby, 2800, Denmark.
Erwin M SchoofDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads B221, Kgs. Lyngby, 2800, Denmark.
Jared L JohnsonMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0003-1802-6527
Chris BakalDynamical Cell Systems Group, Division of Cancer Biology, Institute of Cancer Research, 237 Fulham Road, London, UK.
Lewis C CantleyMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10021, USA.
Roberto ChiarleDepartment of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Justin PritchardDepartment of Biomedical Engineering, Pennsylvania State University, University Park, State College, PA, 16802, USA.
Stevan HubbardDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York, USA.
Brian J P HuntlyDepartment of Haematology, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0312-161X
Michael HemannCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.
Pau CreixellCancer Research UK Cambridge Institute, University of Cambridge, UK.
Michael B YaffeCenter for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research and Departments of Biological Engineering and Biology, Massachusetts Institute of Technology, Cambridge MA, USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7M
Tuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NILES, JACQUIN C · 1985 to 2020
$25.6M
Role of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2M
Protein Kinase Signaling and Cell Cycle ControlR01ES015339 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 2007 to 2017
$4.3M
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphomaR01CA196703 · NCI · BOSTON CHILDREN'S HOSPITAL · PI CHIARLE, ROBERTO · 2015 to 2025
$4.1M
Protein Kinase Signaling in the Genotoxic Stress ResponseR35ES028374 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 2017 to 2024
$3.9M
RNA-Binding Proteins as Molecular Integrators that Control the Response of HGSOC to Ant-Cancer TherapiesR01CA226898 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B, HEMANN, MICHAEL · 2019 to 2023
$2.7M
Modeling human phosphorylation networks through kinome-wide profilingR01GM104047 · NIGMS · YALE UNIVERSITY · PI TURK, BENJAMIN E, YAFFE, MICHAEL B · 2013 to 2017
$2.4M
Investigating functional sites in protein kinases as targets for cancer mutations and novel drugsK99CA226396 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CREIXELL, PAU · 2018 to 2019
$266k
NCI NIH HHS K99 CA226396NCI NIH HHS P01 CA117969NCI NIH HHS P01 CA120964NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA196703NCI NIH HHS R01 CA226898NCI NIH HHS R35 CA197588NIEHS NIH HHS P30 ES002109NIEHS NIH HHS R01 ES015339NIEHS NIH HHS R35 ES028374NIGMS NIH HHS R01 GM104047
6 · The paper itself

Abstract

Protein tyrosine kinases activate signaling pathways by catalyzing the phosphorylation of tyrosine residues in their substrates. Mounting evidence suggests that, in addition to recognizing phosphorylated tyrosine (pTyr) residues through specific phosphobinding modules, many protein kinases selectively recognize pTyr directly adjacent to the tyrosine residue they phosphorylate and catalyze the formation of twin pTyr-pTyr sites. Here, we demonstrate the importance of this phosphopriming-driven twin pTyr signaling in promoting cell cycle progression through the cell cycle-inhibitory protein p27

Identifiers

PMID40661594
PMCPMC12259089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.